Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Melvin Olson
Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA
PLoS ONE
Multidisciplinary
Related publications
Aflibercept for Neovascular Age-Related Macular Degeneration
Cochrane Database of Systematic Reviews
Clinical Experience With Fixed Bimonthly Aflibercept Dosing in Treatment-Experienced Patients With Neovascular Age-Related Macular Degeneration
Clinical Ophthalmology
Ophthalmology
Ranibizumab Versus Verteporfin for Neovascular Age-Related Macular Degeneration
New England Journal of Medicine
Medicine
Safety and Efficacy of Ranibizumab and Bevacizumab for the Treatment of Neovascular Age-Related Macular Degeneration
European Ophthalmic Review
Clinical Risk Factors for Poor Anatomic Response to Ranibizumab in Neovascular Age-Related Macular Degeneration§
Open Ophthalmology Journal
Ophthalmology
Retinal Metabolic and Structural Alterations in Response to Aflibercept Treatment in Neovascular Age‐related Macular Degeneration
Acta Ophthalmologica
Medicine
Ophthalmology
Patterns of Early and Delayed Visual Response to Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration
JAMA Ophthalmology
Ophthalmology
Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data From an Observational Study
Ophthalmology
Ophthalmology
Worsening Anatomic Outcomes Following Aflibercept for Neovascular Age-Related Macular Degeneration in Eyes Previously Well Controlled With Ranibizumab [Corrigendum]
Clinical Ophthalmology
Ophthalmology
